IAVI, Merck KGaA, Serum Institute join hands to develop monoclonal antibodies for Covid-19

The agreement builds on the advanced antibody discovery and optimisation expertise of International AIDS Vaccine Initiative (IAVI) and Scripps Research, and on Germany's Merck KGaA's and Serum Institute's significant capabilities in design and scale up of accelerated manufacturing processes for mAb production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/34kSmsx
via IFTTT